59813-07-9

Upstream product

• 110-85-0 piperazine 
• 120952-09-2 2-bromo-N-ethylpyridinium tetraphenylborate 
• 724788-70-9 8-bromo-7-fluoro-2-methoxy-1,5-naphthyridine 
• 79343-93-4 1-ethyl-2-bromo-pyridinium; bromide 

Downstream Products

• 124953-39-5 (5-phenylisoxazol-3-yl)(piperazin-1-yl)methanone 
• 124953-36-2 (3-Benzyloxy-isoxazol-5-yl)-piperazin-1-yl-methanone 
• 124953-38-4 1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-piperazine 
• 124953-37-3 (3-Phenyl-isoxazol-5-yl)-piperazin-1-yl-methanone 
• 124953-43-1 4-(3-Chloro-isoxazole-5-carbonyl)-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 
• 124953-42-0 4-(3-Bromo-isoxazole-5-carbonyl)-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 
• 124953-44-2 4-(3-Methoxy-isoxazole-5-carbonyl)-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 
• 124953-46-4 4-(3-Phenyl-isoxazole-5-carbonyl)-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 
• 124953-48-6 4-(5-Phenyl-isoxazole-3-carbonyl)-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 
• 124953-49-7 4-[3-(3-Bromo-isoxazol-5-yl)-propionyl]-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 
• 124953-47-5 4-(5-Methyl-3-phenyl-isoxazole-4-carbonyl)-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 

Relevant academic research and scientific papers

OXAZOLIDINONE ANTIBIOTICS

The invention relates to compounds of formula (I) wherein U, V, W, X, R1, R2, R3, R4, R5, R6, A, B, D, E, G, m and n are as defined in the description, to pharmaceutically acceptable salts of such compounds for use in the manufacture of a medicament for the prevention or treatment of a bacterial infection. Certain compounds of formula (I) are new and are also part of this invention.

EFFECT OF THE NATURE OF THE LEAVING GROUP IN REACTIONS OF 2-X-N-ETHYLPYRIDINIUM SALTS WITH AMINES IN ACETONITRILE

The rate-determining stage in the nucleophilic substitution reactions of 2-X-N-ethylpyridinium salts with piperidine in acetonitrile changes, depending on the nature of the leaving group X.In the case where X = Hlg the controlling stage is the formation of the C-N bond.When X = 4-NO2C6H4O3, 3,4-(NO2)2C6H3O, and 2,6-(NO2)2C6H3O, nucleophilic substitution at the carbon atom is controlled by cleavage of the C-X bond.Nucleophilic substitution at a carbon atom of the benzene ring predominates in the reaction of 2-(2,4-dinitrophenoxy)-N-ethylpyridinium salt with piperidine.

ANTIHYPERTENSIVE QUINAZOLINE DERIVATIVES

Novel quinazoline compounds and antihypertensive compositions containing said compounds are disclosed; said compounds having the formula: STR1 wherein R 1 is a hydrogen atom or an alkyl group having 1-5 carbon atoms;R 2 is a group of the formula STR2 in which Y is a hydrogen atom, an alkyl group of 1-5 carbon atoms, an alkoxy group of 1-5 carbon atoms, an alkenyloxy group, a methylenedioxy group, a nitro group, a halogen atom, a trifluoromethyl group, an acyloxy group, a hydroxy group, an unsubstituted or substituted amino group or a condensed benzene nucleus and m is an integer of 1-3 inclusive, or a group of the formula STR3 in which X is an oxygen atom, a sulfur atom or a carbon-nitrogen double bond and Z is a hydrogen atom, an alkyl group of 1-5 carbon atoms, an alkoxy group of 1-5 carbon atoms, a nitro group or a halogen atom; and n is an integer of 2-3 inclusive;provided that, when R 2 is the said group STR4 n is 2 and R 1 is a hydrogen atom or, when R 2 is the said group STR5 n is 2 or 3 and R 1 is a hydrogen atom or the said alkyl group and a pharmaceutically acceptable acid addition salt thereof.